A case of polycythemia vera complicated with portal hypertension and literature review

doi:10.3760/cma.j.issn.1007-1245.2023.22.013

Abstract

Abstract:

Portal hypertension (PHTN) is the clinical syndrome of portal hypertension caused by various reasons. Cirrhosis accounts for 90% of all causes, and polycythemia vera is the main pathogenesis among non-cirrhosis causes. Polycythemia vera is a relatively inert myeloproliferative tumor with increased blood viscosity and complications such as thrombus and bleeding during the disease course. PHTN is a rare complication. This paper reports a case of polycythemia vera complicated with PHTN in First Hospital, Jinan University and summarizes the diagnosis and treatment experience of this disease.

Key words:

Polycythemia vera, Portal vein thrombosis, Portal hypertension, Esophagogastric variceal bleeding

摘要：

门静脉高压（portal hypertension，PHTN）是指由各种原因引起门静脉系统压力增高的临床综合征。肝硬化占所有病因的90%，在非肝硬化病因中，真性红细胞增多症是主要病因。真性红细胞增多症是一种相对惰性的骨髓增殖性肿瘤，患者血液黏滞度升高，病程中可出现血栓和出血等并发症，PHTN是其罕见并发症。现就暨南大学附属第一医院1例真性红细胞增多症合并PHTN的患者进行报道并行文献归纳，总结对该病的诊治体会。

关键词:

真性红细胞增多症, 门静脉血栓形成, 门静脉高压, 食管胃静脉曲张出血

Xie Dihuo, Zhou Hongke.

A case of polycythemia vera complicated with portal hypertension and literature review [J]. International Medicine and Health Guidance News, 2023, 29(22): 3199-3202.

谢帝活周鸿科.

真性红细胞增多症合并门静脉高压1例并文献复习 [J]. 国际医药卫生导报, 2023, 29(22): 3199-3202.

References

[1] 肖志坚.真性红细胞增多症诊断与治疗中国指南(2022年版)[J].中华血液学杂志, 2022, 43(7): 537-541. DOI: 10.3760/cma.j.issn.0253-2727.2022.07.002.
[2] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J]. Blood, 2016, 127(20): 2391-2405. DOI:10.1182/blood-2016-03-643544.
[3] Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances [J]. Am J Hematol, 2016, 91(1): 50-58. DOI:10.1002/ajh.24221.
[4] Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera [J]. Leukemia, 2007, 21(9): 1960-1963. DOI: 10.1038/sj.leu.2404810.
[5] Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study [J]. Leukemia, 2013, 27(9): 1874-1881. DOI: 10.1038/leu.2013.163.
[6] Ruggeri M, Tosetto A, Frezzato M, et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis [J]. Ann Intern Med 2003, 139(6): 470-475. DOI:10.7326/0003-4819-139-6-200309160- 00009.
[7] Iurlo A, Cattaneo D, Bucelli C, et al. New perspectives on polycythemia vera: from diagnosis to therapy [J]. Int J Mol Sci, 2020, 21(16): 5805. DOI: 10.3390/ijms21165805.
[8] Cerquozzi S, Barraco D, Lasho T, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients [J]. Blood Cancer J, 2017, 7(12): 662. DOI: 10.1038/s41408-017-0035-6.
[9] Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology [J]. Blood, 2014, 124(19): 3021-3023. DOI: 10.1182/blood- 2014-07-591610.
[10] Vollmar B, Menger M D. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair [J]. Physiol Rev, 2009, 89(4): 1269-1339. DOI: 10.1152/physrev.00027.2008.
[11] 王文鑫.终末期肝病凝血功能障碍的基础与临床表现研究进展[J].医学研究生学报, 2019, 32(6): 668-672. DOI: 10.16571/j.cnki.1008-8199.2019.06.022.
[12] Zhang L, Wang Y, Lv W, et al. Association of polycythemia vera with non‑cirrhotic portal hypertension in five patients: a case series [J]. Exp Ther Med, 2023, 25(4): 149. DOI: 10.3892/etm.2023.11848.
[13] Khanna R, Sarin S K. Non-cirrhotic portal hypertension - diagnosis and management [J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013.
[14] de Franchis R. Expanding consensus in portal hypertension [J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[15] Yan M, Geyer H, Mesa R, et al. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension [J]. Clin Lymphoma Myeloma Leuk, 2015, 15(1): e1-e5. DOI: 10.1016/j.clml.2014.04.004.
[16] Toros A B, Gokcay S, Cetin G, et al. Portal hypertension and myeloproliferative neoplasms: a relationship revealed [J]. ISRN Hematol, 2013: 673781. DOI: 10.1155/2013/673781.
[17] Sarin SK, Sethi KK, RN. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis [J]. Gut, 1987, 28(3): 260-266. DOI: 10.1136/gut.28.3.260.
[18] 李忠霞, 岳静茹, 王萍.特发性非肝硬化门静脉高压症1例并文献复习[J].江汉大学学报(自然科学版), 2022, 50(2): 64-68. DOI: 10.16389/j.cnki.cn42-1737/n.2022.02.009.
[19] Saab S. Portal hypertension [J]. Clin Liver Dis, 2019, 23(4): xiii-xiv. DOI: 10.1016/j.cld.2019.08.001.
[20] Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis [J]. Gastroenterology, 2019, 156(6): 1582-1599. DOI: 10.1053/j.gastro. 2019.01.265.
[21] 中华医学会肝病学分会.肝硬化诊治指南[J].实用肝脏病杂志,2019,22(6):770-786. DOI: 10.3969/j.issn.1672-5069. 2019.06.004.
[22] Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [J]. J Clin Oncol, 2012, 30(33): 4098-4103. DOI:10.1200/JCO.2012.42.3863.
[23] Mesa RA, Tefferi A. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis [J]. Expert Opin Emerg Drugs, 2009, 14(3): 471-479. DOI:10.1517/14728210903066809.
[24] Spencer RP, Pearson HA. The spleen as a hematological organ [J]. Semin Nucl Med, 1975, 5(1):95-102. DOI: 10.1016/s0001-2998(75)80007-9.
[25] Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis [J]. Hepatology (Baltimore, Md), 2016, 63(5): 1640-1650. DOI: 10.1002/hep.28466.
[26] Nagashima K, Irisawa A, Kashima K, et al. The risk of bleeding in small/straight esophageal varices with red color sign on endoscopy: a retrospective analysis from the natural course [J]. Healthcare (Basel), 2022, 10(7): 1193. DOI: 10.3390/healthcare10071193.
[27] 徐小元, 唐承薇, 令狐恩强.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].中华肝脏病杂志, 2022, 30(10): 1029-1043. DOI: 10.3760 /cmaj.cn501113-20220824- 00436.